Related Experiment Videos
Genetic alterations and chemotherapeutic response in human diffuse gliomas
G J Kitange1, J S Smith, R B Jenkins
1Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA.
Abstract:
Although for many years adjuvant chemotherapy has been used in the management of human diffuse gliomas, the survival of a large proportion of patients with these tumors has remained unchanged. To date, little is known about the factors that render some of these patients resistant to cytotoxic drugs. Since response to chemotherapy has been heterogeneous irrespective of glioma type, it has been proposed that some genetic alterations associated with glioma formation and progression may be responsible for the variations in the sensitivity of these tumors to adjuvant chemotherapy. In this paper, we review the literature and discuss the usefulness of some of the common genetic alterations in predicting chemotherapeutic response in gliomas.
Insights
Chemotherapy resistance in diffuse gliomas is poorly understood. This review explores how genetic alterations may predict patient response to chemotherapy, aiming to improve treatment strategies for these brain tumors.
Area of Science:
- Neuro-oncology
- Cancer Genetics
- Pharmacogenomics
Background:
- Adjuvant chemotherapy is a standard treatment for diffuse gliomas, but patient survival remains largely unchanged.
- Chemotherapy resistance is a significant challenge, with limited understanding of its underlying factors.
- Glioma treatment response is heterogeneous, suggesting a role for genetic factors.
Purpose of the Study:
- To review the literature on genetic alterations in diffuse gliomas.
- To discuss the utility of common genetic alterations in predicting chemotherapeutic response.
- To identify potential biomarkers for personalized glioma treatment.
Main Methods:
- Literature review of studies on glioma genetics and chemotherapy response.
- Analysis of common genetic alterations associated with glioma formation and progression.
- Discussion of the correlation between specific genetic alterations and drug sensitivity.
Main Results:
- Chemotherapy response in gliomas is highly variable.
- Certain genetic alterations are implicated in chemoresistance.
- Understanding these alterations could guide treatment selection.
Conclusions:
- Genetic alterations play a crucial role in determining glioma response to chemotherapy.
- Identifying predictive genetic markers can optimize adjuvant therapy selection.
- Further research into glioma pharmacogenomics is warranted for improved patient outcomes.